| Home | E-Submission | Sitemap | Contact Us |  
top_img
Cancer Research and Treatment > Volume 50(1); 2018 > Article
Amoroso, Erminio, Makin, Pearson, Brock, Valteau-Couanet, Castel, Pasquet, Laureys, Thomas, Luksch, Ladenstein, Haupt, Garaventa, and SIOPEN Group: Topotecan-Vincristine-Doxorubicin in Stage 4 High-Risk Neuroblastoma Patients Failing to Achieve a Complete Metastatic Response to Rapid COJEC: A SIOPEN Study

Abstract

Purpose

Metastatic response to induction therapy for high-risk neuroblastoma is a prognostic factor. In the International Society of Paediatric Oncology Europe Neuroblastoma (SIOPEN) HR-NBL-1 protocol, only patients with metastatic complete response (CR) or partial response (PR) with ≤ three abnormal skeletal areas on iodine 123-metaiodobenzylguanidine ([123I]mIBG) scintigraphy and no bone marrow disease proceed to high dose therapy (HDT). In this study, topotecan-vincristine-doxorubicin (TVD) was evaluated in patients failing to achieve these criteria, with the aim of improving the metastatic response rate.

Materials and Methods

Patients with metastatic high-risk neuroblastoma who had not achieved the SIOPEN criteria for HDT after induction received two courses of topotecan 1.5 mg/m2/day for 5 days, followed by a 48-hour infusion of vincristine, 2 mg/m2, and doxorubicin, 45 mg/m2.

Results

Sixty-three patients were eligible and evaluable. Following two courses of TVD, four (6.4%) patients had an overall CR, while 28 (44.4%) had a PR with a combined response rate of 50.8% (95% confidence interval [CI], 37.9 to 63.6). Of these, 23 patients achieved a metastatic CR or a PR with ≤ 3 mIBG skeletal areas and no bone marrow disease (36.5%; 95% CI, 24.7 to 49.6) and were eligible to receive HDT. Toxicity was mostly haematological, affecting 106 of the 126 courses (84.1%; 95% CI, 76.5 to 90.0), and dose reduction was necessary in six patients. Stomatitis was the second most common nonhematological toxicity, occurring in 20 patients (31.7%).

Conclusion

TVD was effective in improving the response rate of high-risk neuroblastoma patients after induction with COJEC enabling them to proceed to HDT. However, the long-term benefits of TVD needs to be determined in randomized clinical trials.

Introduction

Stage 4 neuroblastoma in children > 18 month of age is still a challenging disease to treat, despite modern therapeutic strategies, with two-thirds of patients refractory to first-line therapy or developing disease progression or relapse after an initial response [1,2].
Rapid COJEC (two courses of carboplatin, etoposide, vincristine; four courses of cisplatin, vincristine; two courses of etoposide, cyclophosphamide) is a time-intensive chemotherapy regimen administered at 10-day intervals that is utilised by the International Society of Paediatric Oncology Europe Neuroblastoma Group (SIOPEN) as the induction therapy for high-risk neuroblastoma patients (SIOPEN HR-NBL-1) [3,4]. Incomplete metastatic response to induction therapy for high-risk neuroblastoma has been shown to be associated with an inferior long-term outcome [5-7]. Therefore, SIOPEN elected for patients with high-risk neuroblastoma only proceeds to high dose therapy (HDT) if the patients have achieved a metastatic complete response (CR) or a “good” partial response (GPR). This is defined as at least a 50% reduction in skeletal iodine 123-metaiodobenzylguanidine([123I]mIBG) positivity and ≤ 3 abnormal skeletal areas on mIBG scintigraphy and no evidence of tumour on bone marrow aspirates and trephines after rapid COJEC. The status of the primary tumour is irrelevant to the decision to proceed to HDT. Given that with COJEC about 31% of patients do not achieve these strict SIOPEN criteria for HDT (Ladenstein R et al., personal communication), further strategies are needed to improve response and increase the number of patients becoming eligible for HDT.
In a previous phase II study of relapsed or refractory patients with neuroblastoma [8], the combination of topotecan given for 5 consecutive days prior to vincristine and doxorubicin administered simultaneously in a 48-hour continuous infusion (topotecan-vincristine-doxorubicin [TVD] regimen) showed a combined response rate (RR) of 64% CR and partial response (PR).
Herein, we report the efficacy and toxicity of the TVD regimen (clinical trials identifier, NCT00392340) given to improve the metastatic response in children following induction therapy in SIOPEN HR-NBL-1, facilitating them to receive HDT with the lowest metastatic burden.

Materials and Methods

This was an open-label, multi-centre, phase II study included in the therapeutic strategy of SIOPEN HR-NBL-1 protocol designed to evaluate the efficacy and toxicity of two courses of TVD in patients with stage 4 high-risk neuroblastoma. Patients eligible for TVD were those in whom the best metastatic response after induction therapy with COJEC was a “poor” PR (PPR, defined as < 50% reduction in skeletal mIBG positivity and/or > three areas of abnormal skeletal uptake on mIBG scintigraphy and/or persistence of tumour on bone marrow aspirate and trephine morphological examination), mixed response (MR), stable disease (SD), or progressive disease (PD) according to the International Neuroblastoma Response Criteria (INRC) [9].
Other eligibility criteria included a absolute neutrophil count (ANC) > 1,000/μL, platelet count > 100,000/μL, creatinine level < 1.5 mg/dL, total bilirubin < 1.2 mg/dL, aspartate aminotransferase, and alanine aminotransferase < 2.5 SD of the reference laboratory, and normal cardiac function on echocardiography. Exclusion criteria included any severe organ dysfunction, known human immunodeficiency virus infection, hepatitis or hepatitis C virus infection and previous treatment with doxorubicin or other treatment besides the COJEC regimen.
According to the TVD regimen, topotecan was administered intravenously as a 30-minute infusion in 0.9% saline in 100 mL/m2 and a dose of 1.5 mg/m2/day for 5 consecutive days. Vincristine was administered in a 48-hour continuous intravenous infusion at a dose of 1 mg/m2/day in 125 mL/m2/day 0.9% saline (maximum dose, 1 mg/day), starting 1 hour after the final topotecan infusion. Doxorubicin was administered intravenously simultaneously with vincristine at a dose of 22.5 mg/m2/day in 125 mL/m2/day of 0.9% saline solution. Granulocyte-colony stimulating factor (filgrastim) was administered at a dose of 5 μg/kg/day subcutaneously starting 48 hours after the end of the TVD course and continuing until neutrophil recovery (ANC > 2,500/μL). Anti-emetic therapy was administered according to institutional policies.
The second course of TVD was scheduled 21-28 days after completion of the first course, following hematologic recovery (ANC > 1,000/μL, platelet count > 100,000/μL), in the absence of clinical evidence of PD and nonhematological toxicity greater than grade 1, according to the Common Terminology Criteria for Adverse Events (http://ctep.cancer. gov). Febrile episodes were classified according to standard international criteria [10].
After completion of the second TVD course, the overall and metastatic tumour response were evaluated by means of a computed tomography or magnetic resonance imaging scan, mIBG scintigraphy, morphological examination of bone marrow aspirates and trephines from at least two sites according to the INRC criteria. However, according to the SIOPEN HR-NBL-1 protocol, only patients achieving metastatic CR or GPR were eligible for HDT. All other patients became eligible for any other salvage treatment (Fig. 1).
Surgical resection of the primary tumour was recommended before HDT, if possible.
The study was approved by national or institutional ethics committees and legal guardians and/or participants were required to provide informed consent prior participation.

1. Statistical methods

For this phase II study, the primary endpoint was the RR after two courses of TVD. Achievement of either a CR, or any PR according to the INRC [9] after two courses of TVD was considered a success, while PD, SD, and MR were considered failures.
The study had a two-stage design according to Simon [11], with an accepted α error of 0.05 and a power of 90%. In this model, a RR < 30% was not considered as interesting (P0), while a RR ≥ 50% was considered sufficient to accept the treatment for further study. According to this design, it was necessary to recruit 24 patients in the first stage, and if at least eight responses (CR or PR) were observed, the study could continue to a total of 63 enrolled patients.
The percentage of patients who achieved the SIOPEN criteria to proceed to HDT and the response of metastases according to metastatic status at study entry were also calculated.
Binomial exact confidence intervals (95% CI) were calculated and reported for all response and toxicity rates. The chi squared test or Fisher exact test, when applicable, were used to compare categorical variables.

Results

1. Baseline characteristics

From April 2007 to October 2009, a total of 65 patients from six European countries (30 centers) were enrolled into the study; two of whom were subsequently excluded (one because of stage 3 disease at diagnosis, one for insufficient data). The characteristics of the remaining 63 (40 males, 23 females) eligible and evaluable patients are summarised in Table 1. The overall response according to INRC at study entry (i.e., after rapid COJEC) was PPR in 40 patients (63.5%), MR in seven (11.1%) patients, SD in 15 (23.8%) patients, and PD in one patient (1.6%). Of the seven patients with an overall MR according to INRC, six had a metastatic PPR and one had metastatic SD. Thus, if only the metastatic response was considered, 46 children (73%) were in PPR, 16 (25.4%) had SD and one (1.6%) had PD. With regard to the metastatic sites, 37 patients (58.7%) had bone marrow involvement, 52 (82.5%) had skeletal mIBG-positive metastatic disease and only one (1.6%) had liver metastases (Table 2).

2. Antitumor activity

According to the statistical design, after enrollment of the first 24 evaluable patients, 10 positive responses (1 CR, 9 PR) were documented; thus, 39 additional patients were recruited to complete the study.

1) Overall response (including primary tumour) according to INRC

Following two courses of TVD, four patients (6.4%) achieved a CR and 28 any PR (44.4%), for an overall RR of 50.8% (95% CI, 37.9 to 63.6). Of the remaining patients, 16 had a MR (25.4%); 14, a SD (22.2%); and 1, a PD (1.6%).

2) Achievement of SIOPEN HR-NBL criteria to proceed to HDT

In addition to the four patients who achieved an overall CR, 14 of the 28 children achieved an overall PR, 10 achieved a metastatic CR and four GPR. Moreover, of the 16 children with an overall MR, three had a metastatic CR and two a GPR. Therefore, 23 patients (36.5%; 95% CI, 24.7 to 49.6; 17 CR and 6 GPR with ≤ 3 mIBG skeletal areas and no bone marrow disease) were eligible to proceed to HDT according to the SIOPEN criteria.
Table 3 reports on the metastatic response after TVD stratified by metastatic response after rapid COJEC. Of the 46 children who entered the study with a PR after rapid COJEC, 20 (43.4%; 14 in CR and six in PR with ≤ 3 mIBG spots) became eligible for HDT, as compared to only three of the 17 who entered the study (18.8%) with either SD or PD, p=0.059.
The response after TVD is reported in Table 2 after stratification by site of metastatic disease. Overall, seven CR (70%) were documented in the 10 patients with only bone marrow disease, five CR and six PR with ≤ 3 mIBG skeletal spots (44%) were documented in the 25 children with only mIBG-positive scan, five CR (18.5%) were documented among the 27 patients with combined positive metastatic disease, and one SD was documented in the only child with hepatic disease. The difference among groups was statistically significant (p=0.012, Fisher exact test). If the metastatic sites were analyzed separately, 17 of the 37 positive bone marrows (45.9%) cleared after TVD, while only 10 of the 52 skeletal metastases (19.2%) achieved CR (p=0.007).
MYCN status did not affect the probability of positive response to TVD. In fact, among the 55 subjects assessed for MYCN, the 13 MYCNamplified patients had a RR (CR or any PR) similar to that of the 42 not amplified (8 [61.5%] vs. 20 [47.6%]; p=0.38, chi-square test). Similarly, six MYCN amplified (46.1%) became eligible for HDT, while versus 15 of the not amplified patients (35.7%) (p=0.53, Fisher exact test).
No difference in achieving the eligibility to HDT was observed after stratification of patients according to MYCN status of their primary tumour.

3. Toxicity

All patients received the two planned TVD courses for a total of 126 evaluable courses. No chemotherapy-related toxic deaths were reported, and the observed toxicity was mostly haematological (Table 4). Overall, 106 courses (84.1%; 95% CI, 76.5 to 90.0) were complicated by grade 3 or 4 neutropenia; 104 (82.5%; 95% CI, 74.8 to 88.7) by grade 3 or 4 thrombocytopenia and 77 (61.1%; 95% CI, 52.0 to 69.7) by grade 3 or 4 anaemia. Slightly more toxicities were observed after the first course (not significant). Only six (9.5%), five (7.9%), 15 (23.8%), and four (6.4%) patients showed no evidence of neutropenia, thrombocytopenia, anaemia or any haematological toxicity, respectively.
Fever was the most frequently reported non-haematological complication documented after 53 courses (42.1%; 95% CI, 33.3 to 51.2). Hospitalization for systemic antibiotic therapy was required following 43 courses (34.1%; 95% CI, 25.9 to 43.1); 25 (39.7%; 95% CI, 27.6 to 52.8) after the first and 18 (28.6%; 95% CI, 17.9 to 41.3) after the second course. Most episodes of fever (48 [90.6%; 95% CI, 79.3 to 97.9]) were classified as fever of unknown origin, and only five (9.4%; 95% CI, 3.1 to 20.7) as documented infection (with one case of bacteraemia that was central venous catheter-related). Stomatitis was the second most common nonhaematological toxicity occurring after 25 courses (19.8%; 95% CI, 13.3 to 27.9) in 20 patients (31.7%). Severe vomiting (grade 3 or 4) was reported after three courses (2.4%; 95% CI, 0.5 to 6.8) in three patients, and severe sensory neuropathy occurred after three courses (3.2%; 95% CI, 0.5 to 6.8) in two patients. Only one case (0.8%; 95% CI, 0.02 to 4.3) of grade 4 constipation was documented.
A 30% dose reduction of the second TVD course was scheduled for the patient with grade 4 constipation. There was a 25% dose reduction in three of the 25 patients with severe stomatitis, and vincristine was only reduced by 50% in two children with severe neuropathy after the first course of TVD.

Discussion

This study provides further evidence of the efficacy of TVD in metastatic neuroblastoma failing to achieve a metastatic CR after rapid COJEC (which does not include topotecan or doxorubicin) according to the SIOPEN HR-NBL-1 protocol. A previous Italian phase II study demonstrated that this combination is effective for treatment of refractory and relapsed (stage 3 and 4) disease, leading to a combined 64% CR and PR RR [8]. The TVD combination was designed based on pre-clinical studies demonstrating that topoisomerase I (campothecins) and II (doxorubicin) inhibitors, if administered in this sequence, have synergistic effects without increased toxicity. In addition, the therapeutic effects of combining topotecan with vincristine were greater than the additive effect of the agents alone with moderate toxicity [12-14]. In the current study, we showed that two courses of TVD improved the response of 36.5% of patients with highrisk neuroblastoma who failed to achieve the SIOPEN HR-NBL criteria after first-line therapy with rapid COJEC, and that these patients are then eligible to proceed to HDT.
In our series, the bone marrow was more likely to be cleared of tumour burden than the skeletal disease. Similarly, patients who entered TVD after having already demonstrated some response to COJEC tended to have a better RR than those who entered TVD after having experienced only SD or PD.
The results reported herein are not fully comparable with those from previous studies that also used topotecan in high-risk neuroblastoma, mainly because of differences in patient selection and schedule of drug administration. In particular, this study only comprised patients with PR, MR, SD, or PD after first-line therapy, while most other studies included patients with both relapsed and refractory disease [15-23]. These previous studies generally reported small and heterogeneous series that received topotecan either alone [15-19] with response rates ranging from < 20% to 60%, or in combination with other drugs including cyclophosphamide [19,20], temozolomide [21,22], or cyclophosphamide-etoposide [23] with response rates ranging from 32% to 64%.
To the best of our knowledge, only two other studies have focused on previously untreated neuroblastoma patients in which topotecan was administered in combination with cyclophosphamide at two different dosages, and the reported response rates were 76% [24] and 84% [25], respectively.
TVD is a manageable therapeutic regimen. In our study, no toxic deaths were observed and schedule reduction was only necessary in six subjects. Myelosuppression was the main treatment-related toxicity. Although hospitalisation for systemic antibiotic therapy was required after 34% of the courses, documented infection was only reported in five patients.
In conclusion, this multi-centre European phase II study demonstrated that the combination of topotecan, vincristine and doxorubicin increased the RR in 36.5% of patients with persistent or refractory high-risk neuroblastoma disease when following an intensive multi-agent induction chemotherapy that does not include topotecan or doxorubicin. Children with only bone marrow disease and those who had already shown some chemo-sensitivity to induction therapy are more likely to benefit from TVD.
Based on the results of this study and because doxorubicin and topotecan are not included in the COJEC regimen, we conclude that the TVD regimen has a role in improving the RR to COJEC induction therapy and thereby in increasing the number of patients eligible for HDT according to the SIOPEN HR-NBL-1 protocol criteria. The long term benefits of TVD compared to other first line chemotherapy combinations need to be determined in randomized clinical trials.

Conflicts of Interest

Conflict of interest relevant to this article was not reported.

Acknowledgments

L. Amoroso and G. Erminio are funded by the Italian Neuroblastoma Foundation. A. D. J. Pearson is funded through a Cancer Research UK Life Chair and Programme Grant included within a Cancer Research UK ICR Core Award (C347/A15403) and is supported by the NIHRRM/ICR Biomedical Research Centre.

Fig. 1.
The topotecan-vincristine-doxorubicin (TVD) salvage therapy for children included in the HR-NBL-1 protocol. Patients with persistent metastatic disease after the COJEC induction therapy of the International Society of Paediatric Oncology Europe Neuroblastoma (SIOPEN) HR-NBL-1 protocol were eligible for TVD therapy with the aim of eradicating the metastatic disease. Children achieving complete remission (CR) or good partial response (GPR) become eligible for consolidation with high dose therapy (HDT) as planned by the original HR-NBL-1 protocol, all the other were considered failures. PPR, poor partial response; MR, mixed response; SD, stable disease; PD, progressive disease.
crt-2016-511f1.tif
Table 1.
Characteristics at diagnosis and at TVD therapy of 63 patients with refractory metastatic neuroblastoma after COJEC induction
Characteristic No. (%)
At diagnosis
 Age, median (IQR, mo) 46 (28-69)
 Primary tumour site
  Abdomen 55 (87.3)
  Chest 6 (9.5)
  Other 2 (3.2)
 Stage 4 63 (100)
MYCN, amplifieda) 13 (23.6)
At study entry
 Overall INRC response post-COJEC
  PR 40 (63.52)
  MR 7 (11.1)
  SD 15 (23.8)
  PD 1 (1.6)
 Metastatic response post-COJEC
  PR 46 (73.0)
  SD 16 (25.4)
  PD 1 (1.6)
 Localization of metastatic disease at TVD entry
  Bone marrow only 10 (15.9)b)
  Skeleton only 25 (39.7)c)
  Combined bone marrow and skeleton 27 (42.9)b),c)
  Liver 1 (1.6)

TVD, topotecan-vincristine-doxorubicin; IQR, interquartile range; INRC, International Neuroblastoma Response Criteria; PR, partial response; MR, mixed response; SD, stable disease; PD, progressive disease; mIBG, metaiodobenzylguanidine.

a) Based on 55 evaluable cases,

b) Total bone marrow positive (n=37),

c) Total mIBG skeleton positive (n=52).

Table 2.
Metastatic response after two courses of TVD by site of metastatic disease at study entry
Site of metastatic disease Metastatic response after TVD
Eligible to HDT
Not eligible to HDT
CR PR ≤ 3 mIBG spots and negative bone marrow PR > 3 mIBG spots and negative bone marrow MR SD PD
Bone marrow only 10 7 (70.0)a) 0 0 0 3 (30.0) 0
Skeleton only 25 5 (20.0)b) 6 (24.0) 4 (16.0) 0 10 (40.0) 0
Combined bone marrow and skeleton 27 5 (18.5)a),b) 0 5 (18.5)a) 16 (59.3) 0 1 (3.7)
Liver 1 0 0 0 0 1 (100) 0
Total 63 17 (27.0) 6 (9.5) 9 (14.3) 16 (25.4) 14 (22.2) 1 (1.6)

Values are presented as number (%). Eligibility to HDT: p=0.012 (Fisher exact test). TVD, topotecan-vincristine-doxorubicin; HDT, high dose therapy; CR, complete response; mIBG, metaiodobenzylguanidine; PR, partial response; MR, mixed response; SD, stable disease; PD, progressive disease.

a) BM cleared,

b) Skeleton cleared.

Table 3.
Metastatic response after TVD stratified by metastatic response after COJEC
Metastatic response after COJEC Metastatic response after TVD
CR PR ≤ 3 mIBG spots and negative bone marrow PR > 3 mIBG spots and negative bone marrow MR SD PD
PR 46 (73.0) 14 (30.4) 6 (13.0) 9 (21.7) 10 (21.7) 7 (15.2) 0
SD 16 (25.4) 3 (18.8) 0 0 6 (37.5) 7 (43.7) 0
PD 1 (1.6) 0 0 0 0 0 1 (100)
Total 63 17 (27.0) 6 (9.5) 9 (14.3) 16 (25.4) 14 (22.2) 1 (1.6)

Values are presented as number (%). Eligibility to HDT: p=0.059 (chi-square test) comparing patients with PR after COJEC vs. those with < PR. TVD, topotecan-vincristine-doxorubicin; CR, complete response; PR, partial response; mIBG, metaiodobenzylguanidine; MR, mixed response; SD, stable disease; PD, progressive disease.

Table 4.
Grade 3-4 toxicity after 126 TVD courses in 63 patients
Toxicity 1st course 2nd course Overall Patients
Hematologic
 Neutropenia 55 (87.3) 51 (80.9) 106 (84.1) 57 (90.5)
 Thrombocytopenia 54 (85.7) 50 (79.4) 104 (82.5) 58 (92.1)
 Anaemia 40 (63.5) 37 (58.7) 77 (61.1) 48 (76.2)
Nonhematologic
 Fever > 38°C 29 (46.0) 24 (38.1) 53 (42.1) 38 (60.3)
 Mucositis 17 (27.0) 8 (12.7) 25 (19.8) 20 (31.7)
 Vomiting 2 (3.2) 1 (1.3) 3 (2.4) 3 (4.8)
 Constipation 1 (1.6) 0 (0.0) 1 (0.8) 1 (1.6)
 Sensory neuropathy 2 (3.2) 1 (1.6) 3 (2.4) 2 (3.2)

Values are presented as number (%). TVD, topotecan-vincristine-doxorubicin.

References

1. Haupt R, Garaventa A, Gambini C, Parodi S, Cangemi G, Casale F, et al. Improved survival of children with neuroblastoma between 1979 and 2005: a report of the Italian Neuroblastoma Registry. J Clin Oncol. 2010;28:2331–8.
crossref pmid
2. Kreissman SG, Seeger RC, Matthay KK, London WB, Sposto R, Grupp SA, et al. Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial. Lancet Oncol. 2013;14:999–1008.
crossref pmid pmc
3. Pearson AD, Pinkerton CR, Lewis IJ, Imeson J, Ellershaw C, Machin D, et al. High-dose rapid and standard induction chemo-therapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial. Lancet Oncol. 2008;9:247–56.
crossref pmid
4. Ladenstein R, Valteau-Couanet D, Brock P, Yaniv I, Castel V, Laureys G, et al. Randomized Trial of prophylactic granulocyte colony-stimulating factor during rapid COJEC induction in pediatric patients with high-risk neuroblastoma: the European HR-NBL1/SIOPEN study. J Clin Oncol. 2010;28:3516–24.
crossref pmid
5. Ladenstein R, Potschger U, Hartman O, Pearson AD, Klingebiel T, Castel V, et al. 28 years of high-dose therapy and SCT for neuroblastoma in Europe: lessons from more than 4000 procedures. Bone Marrow Transplant. 2008;41 Suppl 2:S118–27.
crossref pmid
6. Decarolis B, Schneider C, Hero B, Simon T, Volland R, Roels F, et al. Iodine-123 metaiodobenzylguanidine scintigraphy scoring allows prediction of outcome in patients with stage 4 neuroblastoma: results of the Cologne interscore comparison study. J Clin Oncol. 2013;31:944–51.
crossref pmid
7. Yanik GA, Parisi MT, Shulkin BL, Naranjo A, Kreissman SG, London WB, et al. Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: a report from the Children’s oncology group. J Nucl Med. 2013;54:541–8.
crossref pmid pmc
8. Garaventa A, Luksch R, Biasotti S, Severi G, Pizzitola MR, Viscardi E, et al. A phase II study of topotecan with vincristine and doxorubicin in children with recurrent/refractory neuroblastoma. Cancer. 2003;98:2488–94.
crossref pmid
9. Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993;11:1466–77.
crossref pmid
10. Castagnola E, Mikulska M, Viscoli C. Prophylaxis and empirical therapy of infection in cancer patients. In : Bennett JE, Dolin R, Blaser MJ, editors. Mandell, Douglas, and Bennett’s principles and practice of infectious diseases. New York: Elsevier; 2015. p. 3395–413.

11. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989;10:1–10.
crossref pmid
12. Kim JH, Kim SH, Kolozsvary A, Khil MS. Potentiation of radiation response in human carcinoma cells in vitro and murine fibrosarcoma in vivo by topotecan, an inhibitor of DNA topoisomerase I. Int J Radiat Oncol Biol Phys. 1992;22:515–8.
crossref pmid
13. Rowinsky EK, Verweij J. Review of phase I clinical studies with topotecan. Semin Oncol. 1997;24(6 Suppl 20):S20–3S20.

14. Thompson J, George EO, Poquette CA, Cheshire PJ, Richmond LB, de Graaf SS, et al. Synergy of topotecan in combination with vincristine for treatment of pediatric solid tumor xenografts. Clin Cancer Res. 1999;5:3617–31.
pmid
15. Vassal G, Pondarre C, Cappelli C, Terrier-Lacombe MJ, Boland I, Morizet J, et al. DNA-topoisomerase I, a new target for the treatment of neuroblastoma. Eur J Cancer. 1997;33:2011–5.
crossref pmid
16. Pratt CB, Stewart C, Santana VM, Bowman L, Furman W, Ochs J, et al. Phase I study of topotecan for pediatric patients with malignant solid tumors. J Clin Oncol. 1994;12:539–43.
crossref pmid
17. Blaney SM, Needle MN, Gillespie A, Sato JK, Reaman GH, Berg SL, et al. Phase II trial of topotecan administered as 72-hour continuous infusion in children with refractory solid tumors: a collaborative Pediatric Branch, National Cancer Institute, and Children's Cancer Group Study. Clin Cancer Res. 1998;4:357–60.
pmid
18. Santana VM, Furman WL, Billups CA, Hoffer F, Davidoff AM, Houghton PJ, et al. Improved response in high-risk neuroblastoma with protracted topotecan administration using a pharmacokinetically guided dosing approach. J Clin Oncol. 2005;23:4039–47.
crossref pmid
19. London WB, Frantz CN, Campbell LA, Seeger RC, Brumback BA, Cohn SL, et al. Phase II randomized comparison of topotecan plus cyclophosphamide versus topotecan alone in children with recurrent or refractory neuroblastoma: a Children’s Oncology Group study. J Clin Oncol. 2010;28:3808–15.
crossref pmid pmc
20. Saylors RL 3rd, Stine KC, Sullivan J, Kepner JL, Wall DA, Bernstein ML, et al. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study. J Clin Oncol. 2001;19:3463–9.
crossref pmid
21. Rubie H, Geoerger B, Frappaz D, Schmitt A, Leblond P, Ndiaye A, et al. Phase I study of topotecan in combination with temozolomide (TOTEM) in relapsed or refractory paediatric solid tumours. Eur J Cancer. 2010;46:2763–70.
crossref pmid
22. Di Giannatale A, Dias-Gastellier N, Devos A, Mc Hugh K, Boubaker A, Courbon F, et al. Phase II study of temozolomide in combination with topotecan (TOTEM) in relapsed or refractory neuroblastoma: a European Innovative Therapies for Children with Cancer-SIOP-European Neuroblastoma study. Eur J Cancer. 2014;50:170–7.
crossref pmid
23. Simon T, Langler A, Harnischmacher U, Fruhwald MC, Jorch N, Claviez A, et al. Topotecan, cyclophosphamide, and etoposide (TCE) in the treatment of high-risk neuroblastoma. Results of a phase-II trial. J Cancer Res Clin Oncol. 2007;133:653–61.
crossref pmid
24. Kretschmar CS, Kletzel M, Murray K, Thorner P, Joshi V, Marcus R, et al. Response to paclitaxel, topotecan, and topotecan-cyclophosphamide in children with untreated disseminated neuroblastoma treated in an upfront phase II investigational window: a pediatric oncology group study. J Clin Oncol. 2004;22:4119–26.
crossref pmid
25. Park JR, Scott JR, Stewart CF, London WB, Naranjo A, Santana VM, et al. Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: a Children's Oncology Group study. J Clin Oncol. 2011;29:4351–7.
crossref pmid pmc
TOOLS
PDF Links  PDF Links
PubReader  PubReader
ePub Link  ePub Link
Full text via DOI  Full text via DOI
Download Citation  Download Citation
CrossRef TDM  CrossRef TDM
  E-Mail
  Print
Share:      
METRICS
3
Crossref
2
Scopus
3,169
View
336
Download
Related article
Editorial Office
Korean Cancer Association
Room 1824, Gwanghwamun Officia
92 Saemunan-ro, Jongno-gu, Seoul 03186, Korea
TEL: +82-2-3276-2410   FAX: +82-2-792-1410   E-mail: journal@cancer.or.kr
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
Copyright © Korean Cancer Association. All rights reserved.                 Developed in M2Community